Evidence map›Paper›PMID 28094954›Full record

ArticleMolecular pharmaceutics2017

Backbone Degradable N-(2-Hydroxypropyl)methacrylamide Copolymer Conjugates with Gemcitabine and Paclitaxel: Impact of Molecular Weight on Activity toward Human Ovarian Carcinoma Xenografts.

Jiyuan Yang, Rui Zhang, Huaizhong Pan, Yuling Li, Yixin Fang, Libin Zhang, Jindřich Kopeček

Open access · greenAbstract read
In one paragraph

Article in Molecular pharmaceutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Responsive Supramolecular Polymers for Diagnosis and Treatment.International journal of molecular sciences · 2024
    Review
  5. Review
  6. Article
  7. Evaluation of linear versus star-like polymer anti-cancer nanomedicines in mouse models.Journal of controlled release : official journal of the Controlled Release Society · 2023
    Article
  8. Review
  9. Article
  10. Polymer nanomedicines.Advanced drug delivery reviews · 2020
    Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jiyuan YangTheraTarget, Inc., Salt Lake City, Utah 84112, United States.
Rui Zhang
Huaizhong PanTheraTarget, Inc., Salt Lake City, Utah 84112, United States.
Yuling Li
Yixin Fang
Libin Zhang
Jindřich KopečekORCID 0000-0002-4451-6944
University of Utah · USTheraTarget (United States) · US

Funding

Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian CancerR42CA156933 · NCI · THERATARGET · PI KOPECEK, JINDRICH H. · 2014 to 2015
$995k
NCI NIH HHS R42 CA156933
6 · The paper itself

Abstract

Degradable diblock and multiblock (tetrablock and hexablock) N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-gemcitabine (GEM) and -paclitaxel (PTX) conjugates were synthesized by reversible addition-fragmentation chain-transter (RAFT) copolymerization followed by click reaction for preclinical investigation. The aim was to validate the hypothesis that long-circulating conjugates are needed to generate a sustained concentration gradient between vasculature and a solid tumor and result in significant anticancer effect. To evaluate the impact of molecular weight of the conjugates on treatment efficacy, diblock, tetrablock, and hexablock GEM and PTX conjugates were administered intravenously to nude mice bearing A2780 human ovarian xenografts. For GEM conjugates, triple doses with dosage 5 mg/kg were given on days 0, 7, and 14 (q7dx3), whereas a single dose regime with 20 mg/kg was applied on day 0 for PTX conjugates treatment. The most effective conjugates for each monotherapy were the diblock ones, 2P-GEM and 2P-PTX (Mw ≈ 100 kDa). Increasing the Mw to 200 or 300 kDa resulted in decrease of activity most probably due to changes in the conformation of the macromolecule because of interaction of hydrophobic residues at side chain termini and formation of "unimer micelles". In addition to monotherapy, a sequential combination treatment of diblock PTX conjugate followed by GEM conjugate (2P-PTX/2P-GEM) was also performed, which showed the best tumor growth inhibition due to synergistic effect: complete remission was achieved after the first treatment cycle. However, because of low dose applied, tumor recurrence was observed 2 weeks after cease of treatment. To assess optimal route of administration, intraperitoneal (i.p.) application of 2P-GEM, 2P-PTX, and their combination was examined. The fact that the highest anticancer efficiency was achieved with diblock conjugates that can be synthesized in one scalable step bodes well for the translation into clinics.

Indexed as

AcrylamidesAnimalsCell Line, TumorDeoxycytidineFemaleGemcitabineHumansMiceMice, NudeOvarian NeoplasmsPaclitaxelPolymersXenograft Model Antitumor AssaysAcrylamidesDeoxycytidineGemcitabineN-(2-hydroxypropyl)methacrylamidePaclitaxelPolymersbiodegradable copolymersmacromolecular therapeuticsN-(2-hydroxypropyl)methacrylamide (HPMA)ovarian cancerRAFT polymerization

Identifiers

PMID28094954
PMCPMC8494043
OpenAlexW2571616316

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.